Assessing PSMA in Patients with Progressive Triple-Negative Breast Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the expression of Prostate-Specific Membrane Antigen (PSMA) in patients with progressive metastatic triple-negative breast cancer (TNBC) using Ga-PSMA PET/CT imaging. The aim is to assess the feasibility of molecular radionuclide therapy with Lutetium-177 in patients who have measurable disease identified on prior imaging. Participants will undergo PSMA PET/CT before starting their next line of treatment to determine the potential for targeted therapy. This is a single-center, prospective study designed to gather data on PSMA expression in TNBC lesions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written informed consent in accordance with institutional guidelines and obtained prior to any study procedure
* Women with ≥ 18 years-old
* Eastern Cooperative Oncology Group Performance Status of 0 to 2
* Confirmed diagnosis of progressive metastatic TNBC and presenting measurable disease on 18F-FDG PET/CT (performed within 2 weeks) or Brain MRI in case of progressive brain metastases (performed within 4 weeks) prior to PSMA PET/CT.
* Radiolabelled PSMA PET/CT has to be performed before the next treatment line initiation

Exclusion Criteria:

* Pregnant or lactating patients
* Other active neoplastic disease
* Treatment by another molecule that is the object of investigation within 30 days
* Skin only metastatic disease
* Patients with a significant medical, neuro-psychiatric, or surgical condition, which, in the investigator's opinion, may interfere with completion of the study

Where it's running

• Institut Jules Bordet
  Brussels, Belgium Recruiting

Study contacts

• Study coordinator: Géraldine Gebhart, MD
• Email: geraldine.gebhart@hubruxelles.be
• Phone: 025413095

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging Test for Metastatic Urothelial and Breast C cancers and NSCLC

  This imaging study tests how well the imaging agent works in people with metastatic urothelial cancer, various breast cancers, or NSCLC.

  Recruiting at 4 sites Early Phase 1 RayzeBio, Inc. · St Leonards, New South Wales and 5 other locations · NCT07671092

• Radiotherapy with chemotherapy plus adebrelimab and bevacizumab for TNBC with brain metastases

  This phase II study tests a combination of radiotherapy, cisplatin or carboplatin, adebrelimab, and bevacizumab in adults with triple-negative breast cancer that has spread to the brain.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07638852

• First-line therapy for advanced TNBC with QL1706, plus anlotinib and nab-paclitaxel

  This study tests whether a combination of QL1706 with anlotinib and nab-paclitaxel can help people with newly diagnosed, advanced triple-negative breast cancer.

  Recruiting Phase 2 Jiangsu Cancer Institute & Hospital · Nanjing, Jiangsu · NCT07601178

• Patient-reported outcomes of sacituzumab govitecan versus physician‑choice chemotherapy in Chinese metastatic HER2‑negative breast cancer

  This project will test whether sacituzumab govitecan or physician‑choice chemotherapy leads to better patient‑reported quality of life and symptoms for Chinese adults aged 18–75 with metastatic HER2‑negative breast cancer who progressed after first‑line treatment.

  Recruiting Fudan University · Shanghai, Shanghai Municipality · NCT07551050

• Short-course SBRT plus toripalimab and chemotherapy for chemo-resistant triple-negative breast cancer

  This trial will try a short, high-precision course of breast radiation followed by toripalimab with paclitaxel and carboplatin for people whose triple-negative breast cancer did not shrink after initial chemotherapy to see if it can eliminate invasive cancer at surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT07457359

• Neoadjuvant chemotherapy with sintilimab and bevacizumab for triple-negative breast cancer

  This trial will try adding the immunotherapy drug sintilimab and the blood‑vessel blocker bevacizumab to pre-surgery chemotherapy for women with stage II–III triple‑negative breast cancer to see if more tumors disappear completely before surgery.

  Recruiting at 2 sites Phase 2 First Affiliated Hospital of Zhejiang University · Hefei and 1 other locations · NCT07351487

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.